3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
2
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
1774
Triple Negative Breast Neoplasms
299
Ovarian Neoplasms
135
Lung Neoplasms
115
Colorectal Neoplasms
115
Neoplasms
106
Prostatic Neoplasms
102
Carcinoma, Non-Small-Cell Lung
101
Neoplasm Metastasis
96
Stomach Neoplasms
81
Pancreatic Neoplasms
78
Melanoma
74
Endometrial Neoplasms
64
Head and Neck Neoplasms
60
Uterine Cervical Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
50
Colonic Neoplasms
45
Esophageal Neoplasms
42
Carcinoma, Intraductal, Noninfiltrating
41
Sarcoma
40
Motor Activity
37
HER2-positive Breast Cancer
34
Urinary Bladder Neoplasms
33
Liver Neoplasms
31
Carcinoma, Renal Cell
30
Brain Neoplasms
28
Advanced Breast Cancer
25
Lymphedema
24
Kidney Neoplasms
24
Carcinoma, Transitional Cell
23
Interventions
palbociclib
1
exemestane
1
elacestrant
1
Tamoxifen
1
Letrozole
1
Fulvestrant
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
ER+ Breast Cancer
×
Breast
×
Clear all
NCT06923527
2026-05-12
Circulating Tumor DNA
Yale University
Phase 2
Recruiting
50 enrolled
NCT04985266
2024-12-05
TRAK-ER
Royal Marsden NHS Foundation Trust
Phase 2
Recruiting
1,100 enrolled